News on companion diagnostics and drug/test co-development.
Servier, Qiagen to Develop PCR-Based Companion Diagnostic to Identify IDH1-Mutant Leukemia
Qiagen will develop a real-time PCR-based in vitro diagnostic to identify patients eligible for Servier's Tibsovo and investigational IDH1-targeted agents.
Illumina, Myriad Genetics Expand Partnership to Bring TSO 500 HRD Assay to US
The firms are creating a CDx alliance to help pursue HRD regulatory approvals for both the MyChoice HRD assay and a future clinical IVD test from Illumina.
Point32Health Expands Coverage of Foundation Medicine CDx Tests for Patients With Advanced Cancer
FoundationOne CDx and FoundationOne Liquid CDx comprehensive genomic profiling tests will be available to Point32Health patients with advanced solid tumors.
Roche, Janssen Expand Companion Diagnostic Collaboration
The new agreement allows the companies to collaborate with multiple technologies, including digital pathology and immunoassays.
UnitedHealthcare to Cover Guardant360 for Approved CDx Indications in Lung, Breast Cancer
The move adds coverage for patients not eligible for coverage under Medicare, which currently pays for the test across all tumor types.